Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Ephrin receptor inhibitors act on erythropoietin-producing hepatocellular (Eph) receptor kinases. Eph receptors form the largest family of receptor tyrosine kinases, and the first member was cloned in 1987 from a hepatocellular carcinoma cell line. A-type receptors (EphA) mainly bind ephrin-A ligands anchored by a glycolipid. B-type receptors (EphB) bind ephrin-B ligands that span the membrane of the opposing cell. Contact between cells starts bidirectional signaling into both the receptor cell and the ligand cell. This signaling guides axons, sets tissue boundaries and shapes blood vessels, and it is studied in tumor cell migration. ALW-II-41-27 inhibits several Eph kinases, and EphB4-IN-1 is directed at the EphB4 receptor. UniPR1331 blocks the Eph-ephrin interaction itself, while 150D4 is listed as an EphA4 agonist.
150D4 is a selective agonist of EphA4, capable of effectively penetrating the blood-brain barrier. This compound exhibits excitatory activity and provides neuroprotective effects, making it a valuable tool for studying various neurological conditions. Its unique properties make 150D4 suitable for research aimed at understanding the role of EphA4 in neurobiology and developing potential therapeutic strategies.
Out of stock
All 3 sizes
EphA2 Agonist 1 is a selective agonist for the EphA2 receptor, demonstrating high potency in stimulating EphA2 phosphorylation. This compound exhibits significant effectiveness against glioblastoma cells that overexpress the EphA2 receptor, making it a valuable tool for research in cancer biology and therapeutic development. Its ability to activate EphA2 pathways can aid in elucidating the receptor's role in tumorigenesis and potential interventions.
123B9 is a potent and selective agonist of the EphA2 receptor, exhibiting a Kd value of 4.0 μM. This compound selectively binds to the ligand-binding domain of the EphA2 tyrosine kinase receptor, facilitating downstream signaling pathways. Importantly, 123B9 does not significantly affect the ligand-binding domains of the closely related EphA3 and EphA4 receptors, making it a valuable tool for targeted studies in cancer research and therapeutic applications involving EphA2 signaling.
EphA2 agonist 2 is a selective agonist targeting the EphA2 receptor, known for its antitumor properties. This compound demonstrates the ability to cross the blood-brain barrier, making it a valuable tool for research in cancer therapeutics and neuro-oncology. Its specificity for EphA2 may aid in elucidating the role of this receptor in tumor progression and could assist in the development of innovative treatment strategies.
